Related coverage linked through entity extraction aliases.
Apr 03, 2026
April 2 biotech value screen names Bicycle Therapeutics, Novavax, and PTC Therapeutics. Novavax earned an A Value Grade; February screens included Arcturus, Emergent, Puma, Rigel, and Sutro.
Jun 29, 2026
Two recent court decisions impact pharmaceutical trade secret litigation. A U.S. District Court dismissed a lawsuit by PTC Therapeutics against former employees, finding no plausible allegation of misappropriation. Separately, the Federal Circuit ruled that it retains jurisdiction over trade secret claims even after voluntary dismissal of patent claims, providing defendants with a clearer path to appellate review.
Feb 12, 2026
PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy following FDA feedback that the data are unlikely to meet the threshold for substantial evidence of effectiveness.
